14:19 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers

DISEASE CATEGORY: Cancer INDICATION: Lung; leukemia; lymphoma; solid tumors Cell and mouse studies suggest inhibiting MAT2A could help treat lung and other solid and liquid cancers. In a panel of human cancer cell lines, including...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methionine adenosyltransferase 2A (MAT2A); protein arginine methyltransferase 5 (PRMT5); RIO kinase 1 (RIOK1); methylthioadenosine phosphorylase (

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting the MAT2A / PRMT5 / RIOK1 axis could help treat MTAP-deficient colon cancer. In a human MTAP-deficient colon cancer cell line, shRNA targeting MAT2A,...